PEG-PAL: Phase I data

In an open-label Phase I trial in 25 patients, a single subcutaneous injection of 0.1 mg/kg PEG-PAL led to a mean reduction of 62% in blood phenylalanine levels from baseline. The first 4 cohorts of 0...